select search filters
briefings
roundups & rapid reactions
before the headlines
Fiona fox's blog
The press release from Valneva states that initial results show excellent immune response after a third dose of VLA2001 administered 7 to 8 months after the second dose of primary vaccination.
Please note Adam is Chief Investigator of the Valneva vaccine clinical development programme in the UK; see full declaration of interests below.
Prof Adam Finn, Professor of Paediatrics, University of Bristol, said:
“These results demonstrate that two doses of the whole virion inactivated adjuvanted Valneva vaccine, even at a low dose, prime for a large anamnestic (memory) antibody response when a full dose booster of the same vaccine is administered some months later. This is an expected finding and another important step forward in assembling the evidence to support the authorisation and use of this vaccine. We expect to receive related functional (virus neutralisation) assay results shortly as well as information about cross neutralisation of the Omicron variant. We hope to be able to obtain more information about boosting with this vaccine in the ongoing phase 3 study being conducted in the UK early in 2022. Meantime the process of application for authorisation with MHRA and EMA based on existing safety and immunogenicity data is ongoing. I am optimistic that this vaccine – which is a different platform from all those currently in use or approaching authorisation in Europe – will become available in the coming months adding to the range of tools available to us to combat the ongoing pandemic and thus our resilience in the face of this agile and dangerous virus.”
All our previous output on this subject can be seen at this weblink:
www.sciencemediacentre.org/tag/covid-19
Declared interests
Prof Adam Finn: “AF is Chief Investigator of the Valneva vaccine clinical development programme in the UK. He receives no remuneration for this work over and above his salary from the University of Bristol and has no personal or family financial or intellectual property assets related to this company or any other vaccine developer or manufacturer.
AF is an investigator in several COVID19 vaccine trials and studies including Oxford-AstraZeneca, Pfizer, Janssen and Valneva vaccines and several UK government-funded studies involving more than one vaccine. He is U.K. Chief Investigator Sanofi COVID19 booster vaccine trial. He is an advisor to the UK government as a member of JCVI. He chairs the WHO Euro Technical Advisory Group of Experts and is a member of the WHO Special Advisory Group of Experts Working Group on COVID19 vaccines. He undertakes consultancy work for several vaccine developers. He receives no personal remuneration for any of this work, owns no IP or stocks and shares and is paid only in his role as Professor of Paediatrics at the University of Bristol.”